ALGN
Wall Street’s brushing its teeth again
Citigroup’s Daniel Grosslight started coverage on Align Technology with a Buy rating and a $240 price target. That’s a pretty clear message: Citi thinks the Invisalign maker still has more upside left in the tank.
Why investors should care
Align’s stock was cited around $186.63, so Citi’s target implies a decent chunk of runway from here. In other words, the market isn’t being told to sprint — but it is being told to keep jogging in the same direction.
A few things are doing the heavy lifting here:
- Align keeps expanding its product lineup
- Its market presence is still growing
- Analysts broadly seem to be warming up to the name
The vibe check on ALGN
This kind of initiation doesn’t change the business overnight, but it can matter. Fresh coverage from a major bank often nudges investors who’ve been sitting on the sidelines like, “Okay, maybe I should look at this again.”
And yes, the article also flags $1.5 million in insider sales over the last three months. That’s not exactly a parade of confidence from the inside crowd, but it’s also not unusual enough on its own to outweigh a bullish analyst call.
Big picture
Net-net, this is a classic Wall Street reset: one big bank says the stock looks attractive, and suddenly the market has to ask whether Align’s next chapter is still upside — or just less boring than people thought.